Vitiligo en niños: enfoque clínico.

Solapas principales

-A A +A
Artículo de revisión
Rev Asoc Colomb Dermatol. 2018; 26 : 2 (abril - junio), 116-125

Vitiligo en niños: enfoque clínico.

Vitiligo in children: clinical approach.
Autor(es): 
Dra. Claudia Juliana Díaz
claudia.diaz@correounivalle.edu.co
Médica dermatóloga; docente, Universidad del Valle, Hospital Universitario del Valle Evaristo García, E.S.E., Santiago de Cali, Colombia
Dr. Jairo Hernán Rodríguez
Médico, residente de tercer año de Dermatología y Cirugía Dermatológica, Universidad del Valle, Hospital Universitario del Valle Evaristo García, E.S.E., Santiago de Cali, Colombia
Resumen: 

El vitíligo es una enfermedad despigmentante que afecta entre el 1 y el 2 % de la población mundial y cerca de la mitad de los casos se inician en la infancia. Los estudios de prevalencia en diferentes poblaciones de niños, adolescentes y adultos, muestran porcentajes similares en diferentes países del mundo. Hasta el momento, existen pocos estudios de seguimiento a largo plazo sobre el tratamiento en niños; la mayoría de las publicaciones se enfocan en conceptos preexistentes que son básicos en el estudio y la aproximación terapéutica del paciente pediátrico con vitíligo. En esta revisión, se resumen la clasificación, las generalidades, las enfermedades asociadas al vitíligo segmentario y no segmentario, las alteraciones psicológicas que presentan los niños afectados por esta condición y sus padres, y el tratamiento, con énfasis en la ‘evidencia’ clínica sobre los medicamentos más usados.

Palabras clave: 
Vitiligo, niños, tratamiento

Summary: 

Vitiligo is a depigmenting disease that affects between 1 and 2% of the world population and about half of the cases begin in childhood. The prevalence studies in different populations in children, adolescents and adults show similar percentages in different countries of the world. So far, there are few long-term follow-up studies regarding treatment in children. Most of the publications focus on preexisting concepts that are basic in the study and in the therapeutic approach of the pediatric patient with vitiligo. In this review, we summarize its classification, generalities, diseases associated with segmental and non-segmental vitiligo, the psychological alterations presented by children affected by this condition and their parents, and the treatment emphasizing the clinical evidence of the most commonly used medications.

Key words: 
Vitiligo, children, treatment
PDF del articulo

Referencias

1. Kruger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol. 2012;51:1206-12.

2. Sehgal VN, Srivastava G. Vitiligo: Compendium of clinico-epidemiological features. Indian J Dermatol Venereol Leprol. 2007;73:149-56.

3. Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386:74-84.

4. Taieb A, Morice-Picard F, Jouary T, Ezzedine K, et al. Segmental vitiligo as the possible expression of cutaneous somatic mosaicism: Implications for common non-segmental vitiligo. Pigment Cell Melanoma Res. 2008;21:646-52.

5. Ezzedine K, Le Thuaut A, Jouary T, Ballanger F, Taieb A, Bastuji-Garin S. Latent class analysis of a series of 717 patients with vitiligo allows the identification of two clinical subtypes. Pigment Cell Melanoma Res. 2014;27:134-9.

6. Xianfeng C, Yuegen J, Zhiyu Y, Yan Y, Xuesi Z, Fenglai W, et al. Pediatric patients with vitiligo in eastern China: Abnormalities in 145 cases based on thyroid function tests and Immunological findings. Med Sci Monit. 2015;21:3216-21.

7. Kakourou T, Kanaka-Gantenbein C, Papadopoulou A, Kaloumenou E, Chrousos GP. Increased prevalence of chronic autoimmune (Hashimoto's) thyroiditis in children and adolescents with vitiligo. J Am Acad Dermatol. 2005;53:220-3.

8. Baldini E, Odorisio T, Sorrenti S, Catania A, Tartaglia F, Carbotta G, et al. Vitiligo and autoimmune thyroid disorders. Front Endocrinol (Lausanne). 2017;27:290.

9. Aslan S, Serarslan G, Teksoz E, Dagli S. Audiological and transient evoked otoacoustic emission findings in patients with vitiligo. Otolaryngol Head Neck Surg. 2010;142:409-14.

10. Chen YT, Chen YJ, Hwang CY, Lin MW, Chen TJ, Chen CC, et al. Comorbidity profiles in association with vitiligo: A nationwide population-based study in Taiwan. J Eur Acad Dermatol Venereol. 2015;29:1362-9.

11. Sharma CK, Sharma M, Prasad K. Involvement of different genes expressions during immunological and inflammatory responses in vitiligo.Crit Rev Eukaryot Gene Expr. 2017;27:277-87.

12. Spritz RA, Andersen GH. Genetics of vitiligo.Dermatol Clin. 2017;35:245-55.

13. Dammak I, Boudaya S, Ben Abdallah F, Turki H, Attia H, Hentati B. Antioxidant enzymes and lipid peroxidation at the tissue level in patients with stable and active vitiligo. Int J Dermatol. 2009;48:476-80.

14. Speeckaert R, van Geel N. Vitiligo: An update on pathophysiology and treatment options. Am J Clin Dermatol. 2017;18:733-44.

15. Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE, Vitiligo Working Group. New discoveries in the pathogenesis and classification of vitiligo. J Am Acad Dermatol. 2017;77:1-13.

16. Elela MA, Hegazy RA, Fawzy MM, Rashed LA, Rasheed H. Interleukin 17, interleukin 22 and FoxP3 expression in tissue and serum of non-segmental vitiligo: A case-controlled study on eighty-four patients. Eur J Dermatol. 2013;23:350-5.

17. Chatterjee S, Eby JM, Al-Khami AA, Soloshchenko M, Kang HK, Kaur N, et al. A quantitative increase in regulatory T cells controls development of vitiligo. J Invest Dermatol. 2014;134:1285-94

18. Dong J, An X, Zhong H, Wang Y, Shang J, Zhou J. Oncotarget. 2017;8:109161-74.

19. Barygina V, Becatti M, Lotti T, Moretti S, Taddei N, Fiorillo C. Treatment with low-dose cytokines reduces oxidative-mediated injury in perilesional keratinocytes from vitiligo skin. J Dermatol Sci. 2015;79:163-70. 

20. Lotti T, Hercogova J, Wollina U, Chokoeva AA, Zarrab Z, Gianfaldoni S, et al. Vitiligo: Successful combination treatment based on oral low dose cytokines and different topical treatments. J Biol Regul Homeost Agents. 2015;29(Suppl.):53-8.

21. Ezzedine K, Lim HW, Suzuki T, Katayama I, Hamzavi I, Lan CC, et al. Revised classification/nomenclature of vitiligo and related issues: The Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2012;25:E1-13.

22. van Geel N, De Lille S, Vandenhaute S, Gauthier Y, Mollet I, Brochez L, et al. Different phenotypes of segmental vitiligo based on a clinical observational study. J Eur Acad Dermatol Venereol. 2011;25:673-8.

23. Silverberg NB. Pediatric vitiligo. Pediatr Clin North Am. 2014;61:347-66.

24. Prcic S, Djuran V, Katanic D, Vlaski J, Gajinov Z. Vitiligo and thyroid dysfunction in children and adolescents. Acta Dermatovenerol Croat. 2011;19:248- 54.

25. Weyant GW, Chung CG, Helm KF. Halo nevus: Review of the literature and clinicopathologic findings. Int J Dermatol. 2015;54:433-5.

26. Zhou H, Wu LC, Chen MK, Liao QM, Mao RX, Han JD. Factors associated with development of vitiligo in patients with halo nevus. Chin Med J (Engl). 2017:20;130:2703-8.

27. Diaz-Angulo S, López-Hoyos M, Muñoz-Cacho P, López-Escobar M, González-López MA. High prevalence of thyroid autoimmunity in patients with alopecia areata and vitiligo: A controlled study. Australas J Dermatol. 2015;56:142-3.

28. Anbar TS, El-Badry MM, McGrath JA, Abdel-Azim ES. Most individuals with either segmental or nonsegmental vitiligo display evidence of bilateral cochlear dysfunction. Br J Dermatol. 2015;172:406-11.

29. Silverberg JI, Silverberg AI, Malka E, Silverberg NB. A pilot study assessing the role of 25 hydroxy vitamin D levels in patients with vitiligo vulgaris. J Am Acad Dermatol. 2010;62:937-41.

30. Silverberg NB. Recent advances in childhood vitiligo. Clin Dermatol. 2014;32:524-30.

31. Amer AA, Mchepange UO, Gao XH, Hong Y, Qi R, Wu Y, et al. Hidden victims of childhood vitiligo: Impact on parents' mental health and quality of life. Acta Derm Venereol. 2015;95:322-5.

32. Silverberg JI, Silverberg NB. Quality of life impairment in children and adolescents with vitiligo. Pediatr Dermatol. 2014;31:309-18.

33. Sánchez G, Araluce M. Vitiligo: aspectos psicológicos. Rev Hosp Psiquiatr Habana. 1988;29:463-76.

34. Cupertino F, Niemeyer-Corbellini JP, Ramos-ESilva M. Psychosomatic aspects of vitiligo. Clin Dermatol. 2017;35:292-7.

35. van Driessche F, Silverberg N. Current management of pediatric vitiligo. Paediatr Drugs. 2015;17:303-13.

36. Taieb A, Alomar A, Bohm M, Dell'anna ML, De Pase A, Eleftheriadou V, et al. Guidelines for the management of vitiligo: The European Dermatology Forum consensus. Br J Dermatol. 2013;168:5- 19.

37. de Menezes AF, Oliveira de Carvalho F, Barreto RS, de Santana Silva B, Shanmugam S, Gurgel RQ, et al. Pharmacologic treatment of vitiligo in children and adolescents: A systematic review. Pediatr Dermatol. 2017;34:13-24.

38. Kose O, Arca E, Kurumlu Z. Mometasone cream versus pimecrolimus cream for the treatment of childhood localized vitiligo. J Dermatolog Treat. 2010;21:133-9.

39. Kwon HB, Choi Y, Kim HJ, Lee AY. The therapeutic effects of a topical tretinoin and corticosteroid combination for vitiligo: A placebo-controlled, paired-comparison, left-right study. J Drugs Dermatol 2013;12:63-7.

40. Parsad D, Saini R, Juneja A. Combination of clobetasol and tretinoin in vitiligo. Int J Dermatol. 2000;39:639-40.

41. Coskun B, Saral Y, Turgut D. Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo. Eur J Dermatol. 2005;15:88-91.

42. Wong R, Lin AN. Efficacy of topical calcineurin inhibitors in vitiligo. Int J Dermatol. 2013;52:491-6.

43. Silverberg NB, Lin P, Travis L, Farley-Li J, Mancini AJ, Wagner AM, et al. Tacrolimus ointment promotes repigmentation of vitiligo in children: A review of 57 cases. J Am Acad Dermatol. 2004;51:760-6.

44. Grimes PE, Soriano T, Dytoc MT. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol. 2002;47:789-91.

45. Li R, Qiao M, Wang X, Zhao X, Sun Q . Effect of narrow band ultraviolet B phototherapy as monotherapy or combination therapy for vitiligo: A meta-analysis. Photodermatol Photoimmunol Photomed. 2017;33:22-31.

46. Gargoom AM, Duweb GA, Elzorghany AH, Benghazil M, Bugrein OO. Calcipotriol in the treatment of childhood vitiligo. Int J Clin Pharmacol Res. 2004;24:11-4.

47. Vásquez-López F, López-Escobar M, Pérez-Oliva N. Calcipotriene and vitiligo. Arch Dermatol. 2003;139:1656-7.

48. Parsad D, Saini R, Nagpal R. Calcipotriol in vitiligo: A preliminary study. Pediatr Dermatol. 1999;16:317-20.

49. Majid I, Imran S. Relapse after methylprednisolone oral minipulse therapy in childhood vitiligo: A 12-month follow-up study. Indian J Dermatol. 2013;58:113-6.

50. Majid I, Masood Q, Hassan I, Khan D, Chisti M. Childhood vitiligo: Response to methylprednisolone oral minipulse therapy and topical fluticasone combination. Indian J Dermatol. 2009;54:124-7.

51. Kanwar AJ, Dogra S. Narrow-band UVB for the treatment of generalized vitiligo in children. Clin Exp Dermatol. 2005;30:332-6.

52. Koh MJ, Mok ZR, Chong WS. Phototherapy for the treatment of vitiligo in Asian children. Pediatr Dermatol. 2015;32:192-7.

53. Njoo MD, Bos JD, Westerhof W. Treatment of generalized vitiligo in children with narrow-band (TL01) UVB radiation therapy. J Am Acad Dermatol. 2000;42:245-53.

54. Gianfaldoni S, Tchernev G, Wollina U, Lotti J, Rovesti M, Satolli F, et al. Vitiligo in children: What's new in treatment? Open Access Maced J Med Sci. 2018;6:221-5.

55. Bae JM, Yoo HJ, Kim H, Lee JH, Kim GM. Combination therapy with 308-nm excimer laser, topical tacrolimus, and short-term systemic corticosteroids for segmental vitiligo: A retrospective study of 159 patients. J Am Acad Dermatol. 2015;73:76-82.

56. Hui-Lan Y, Xiao-Yan H, Jian-Yong F, Zong-Rong L. Combination of 308-nm excimer laser with topical pimecrolimus for the treatment of childhood vitiligo. Pediatr Dermatol. 2009;26:354-6.

57. Saraceno R, Nistico SP, Capriotti E, Chimenti S. Monochromatic excimer light 308 nm in monotherapy and combined with topical khellin 4% in the treatment of vitiligo: A controlled study. Dermatol Ther. 2009;22:391-4.

58. Ostovari N, Passeron T, Zakaria W, Fontas E, Larouy JC, Blot JF. Treatment of vitiligo by 308-nm excimer laser: An evaluation of variables affecting treatment response. Lasers Surg Med. 2004;35:152-6.

59. Bae JM, Jung HM, Hong BY, Lee JH, Choi WJ, Lee JH, et al. Phototherapy for Vitiligo: A systematic review and meta-analysis. JAMA Dermatol. 2017;153:666-74.

60. Calzavara-Pinton PG, Ortel B, Carlino AM, Honigsmann H, De Panfilis G. Phototesting and phototoxic side effects in bath PUVA. J Am Acad Dermatol. 1993;28:657-9.

61. Koulu LM, Jansén CT. Skin phototoxicity variations during repeated bath PUVA exposures to 8-methoxypsoralen and trimethylpsoralen. Clin Exp Dermatol. 1984;9:64-9.

62. Valkova S, Trashlieva M, Christova P. Treatment of vitiligo with local khellin and UVA: comparison with systemic PUVA. Clin Exp Dermatol. 2004;29:180-4.

63. Carlie G, Ntusi NB, Hulley PA, Kidson SH. KUVA (khellin plus ultraviolet A) stimulates proliferation and melanogenesis in normal human melanocytes and melanoma cells in vitro. Br J Dermatol. 2003;149:707-17.

64. Camacho F, Mazuecos J. Oral and topical L-phenylalanine, clobetasol propionate, and UVA/sunlight--a new study for the treatment of vitiligo. J Drugs Dermatol. 2002;1:127-31.

65. Camacho F, Mazuecos J. Treatment of vitiligo with oral and topical phenylalanine: 6 years of experience. Arch Dermatol. 1999;135:216-7.

66. Matin R. Vitiligo in adults and children: Surgical interventions. BMJ Clin Evid. 2015:20;2015.

67. Mulekar SV, Isedeh P. Surgical interventions for vitiligo: An evidence-based review. Br J Dermatol. 2013;169:57-66.

68. Lahiri K. Evolution and evaluation of autologous mini punch grafting in vitiligo. Indian J Dermatol. 2009;54:159-67.

69. Dillon AB, Sideris A, Hadi A, Elbuluk N. Advances in vitiligo: An update on medical and surgical treatments. J Clin Aesthet Dermatol. 2017;10:15-28.

70. Falabella R. The minigrafting test for vitiligo: Validation of a predicting tool. J J Am Acad Dermatol. 2004;51:672-3.

71. Falabella R. Treatment of localized vitiligo by autologous minigrafting. Arch Dermatol. 1988;124:1649-55.

.
Rev Asoc Colomb Dermatol. 2018; 26: 2 (abril - junio), 86-87
.
Rev Asoc Colomb Dermatol. 2018; 26 : 2 (abril - junio), 90-91
Confidential handling of information.
Rev Asoc Colomb Dermatol. 2018; 26 : 2 (abril - junio), 92-93
Diagnostic concordance between clinical and dermatoscopic digital images’ evaluation versus face to face evaluation of skin tumors.
Rev Asoc Colomb Dermatol. 2018; 26 : 2 (abril - junio), 94-105
Clinical characteristics and phototherapy response of patients with psoriasis.
Rev Asoc Colomb Dermatol. 2018; 26 : 2 (abril - junio), 106-115
Vitiligo in children: clinical approach.
Rev Asoc Colomb Dermatol. 2018; 26 : 2 (abril - junio), 116-125
Elephantiasis nostras verrucosa in a patient with primary lymphedema, case report.
Rev Asoc Colomb Dermatol. 2018; 26 : 2 (abril - junio), 126-131
Ulcerated congenital digital child fibromatosis, case report.
Rev Asoc Colomb Dermatol. 2018; 26 : 2 (abril - junio), 132-136
Importance of the multidisciplinary approach in patients with hypohidrotic ectodermal dysplasia: About three cases in a family.
Rev Asoc Colomb Dermatol. 2018; 26 : 2 (abril - junio), 138-143
.
Rev Asoc Colomb Dermatol. 2018; 26 : 2 (abril - junio), 144-145
Confidential handling of information.
Rev Asoc Colomb Dermatol. 2018; 26 : 2 (abril - junio), 146-148

PATROCINADORES PRINCIPALES

  • MEDIHEALTH
  • SESDERMA
  • MD FARMACIA MAGISTRAL
  • EPIDERMIQUE
  • ISDIN
  • GALDERMA